Drug Type: Stem Cell Therapy
Conditions: ALS, diabetes mellitus
Mechanism Type: Neuroprotection
Mechanism: AstroRx is an experimental cell-based therapy. The approach involves the delivery of human embryonic stem cell-derived astrocyte precursor cells by intrathecal transplantation. The introduction of functional astrocyte precursor cells has the potential to regulate glutamatergic signaling, which is impaired in ALS patients, and thereby reduce neurotoxicity. Transplantation of astrocytes derived from stem cells into mutant SOD1 rats increases survival.
U.S. Status for ALS: Phase I/IIA (Israel)
 To Lead the Field of ALS Treatment Worldwide: Kadimastem Announces Strategic Collaboration with Korean Biotech Company Corestem, Including a $7M Investment in Kadimastem Kadimastem, 7 Dec 2016. Accessed 8 Feb 2018 from https://www.prnewswire.com/news-releases/to-lead-the-field-of-als-treatment-worldwide-kadimastem-announces-strategic-collaboration-with-korean-biotech-company-corestem-including-a-7m-investment-in-kadimastem-605210986.html
 Kadimastem. Regenerative Medicine – Neurodegenerative Diseases. Kadimastem, n.d. Accessed 9 Mar 2016 from http://www.kadimastem.com/regenerative-medicine/18/neurodegenerative-diseases.
 Kadimastem Reached Agreements with the FDA Regarding the Framework of the Clinical Trials in Humans for the Treatment of ALS. BusinessWire, 10 Dec 2015. Accessed 9 Mar 2016 from http://www.businesswire.com/news/home/20151210005420/en/Kadimastem-Reached-Agreements-FDA-Framework-Clinical-Trials.
Last updated March 9th, 2019